2,3-dihydroxypropyl N-propylcarbamate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: 2,3-dihydroxypropyl N-propylcarbamate
• 化学式: C₇H₁₅NO₄
• 分子量: 177.2
• InChiKey: ZHEJDSPAGQQOSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY<br/>[FR] CONJUGUÉS CYSTÉAMINE-ACIDE GRAS ET LEUR UTILISATION COMME ACTIVATEURS DE L'AUTOPHAGIE
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2016086103A1

  公开（公告）日：2016-06-02

  The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNG1E), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy- encephalomyopathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)-N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z,8Z, 11Z, 14Z, 17Z)-N-(2-mercaptoethyl) icosa-5, 8,11,14, 17-pentaenamide.

  该发明涉及（i）6-成员杂环芳基取代脂肪酸半胱氨酸共轭物，其组合物，治疗涉及自噬失调的疾病的方法，如囊性纤维化，特发性肺纤维化（IPF），神经退行性疾病，炎症性疾病，肝病，肌肉疾病，感染和免疫疾病，使用该化合物，或（ii）治疗特发性肺纤维化，线粒体疾病，利氏综合征，糖尿病和耳聋（DAD），莱伯遗传性视神经病变，神经病性-共济失调-视网膜色素变性和上睑下垂（NARP），神经肌性胃肠病（MNG1E），带有皱纹红纤维的肌阵挛性癫痫（MERRF），或线粒体肌病-脑病-乳酸中毒性中风样症状（MELAS），包括向患者给予脂肪酸半胱氨酸共轭物，（4Z，7Z，10Z，13Z，16Z，19Z）-N-（2-巯基乙基）二十二碳四烯酰胺或（5Z，8Z，11Z，14Z，17Z）-N-（2-巯基乙基）二十碳五烯酰胺。
• FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：US20170258741A1

  公开（公告）日：2017-09-14

  The invention relates to (i) 6-membered heteroaryl substituted fatty acid cystamine conjugates, compositions thereof, methods of treating diseases involving dysregulation of autophagy, such as cystic fibrosis, idiopathic pulmonary fibrosis (IPF), a neurodegenerative disease, inflammatory disease, liver disease, muscle disease, infection and immune disease with this compound, or (ii) a method of treating idiopathic pulmonary fibrosis, mitochondrial diseases, Leigh Syndrome, Diabetes Mellitus and Deafness (DAD), Leber's hereditary optic neuropathy, Neuropathy-ataxia-retinis pigmentosa and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNG1E), myoclonic epilepsy with ragged red fibers (MERRF), or mitochondrial myopathy-encephalomy-opathy-lactic acidosis stroke like symptoms (MELAS), comprising administering to a patient the fatty acid cysteamine conjugate, (4Z, 7Z. 10Z, 13Z, 16Z, 19Z)—N-(2-mercaptoethyl) docosa-4,7,10,13,16,19-hexaenamide or (5Z, 8Z, 11Z, 14Z, 17Z)—N-(2-mercaptoethyl) icosa-5,8,11,14,17-pentaenamide.